Dr. Pavic on masitinib plus docetaxel in first-line mCRPC

Body: In this video, Michel Pavic, MD, discusses the background and findings of the study, “Masitinib plus docetaxel as first-line treatment of metastatic castrate refractory prostate cancer: results from study AB12003,” presented recently at the 2021 American Urological Association Annual Meeting. Pavic is an oncologist and head of the hematology-oncology service at CIUSSS de l’Estrie (CHUS) and a professor of medicine and health sciences at the University of Sherbrooke, Quebec, Canada.